×
0 -0.0197222222222224 -0.00694444444444445 -0.00694444444444445 -0.0130555555555557 -0.0277083333333334 0.00694444444444445 0.00909722222222214
Stockreport

EMA tags PhaseRx's lead product candidate an Orphan Drug for rare enzyme deficiency disorder; shares ahead 13% [Seeking Alpha]

PHASERX (PZRX)  More Company Research Source: Seeking Alpha
US:NASDAQ Investor Relations: investor.phaserx.com/investors/default.aspx
PDF Thinly traded nano cap PhaseRx ( PZRX ) is up on a 34x surge in volume in response to the news that the European Medicines Agency has designated lead product candidate PRX-OTC an Orphan Drug for the treatment of ornithine transcarbamylase deficiency, a rare inherited disorder that causes ammonia to accumulate in the blood. IND-stage PRX-OTC is a therapeutic designed to deliver the mRNA encoding the missing enzyme into liver cells. Among the benefits of Orphan Drug status in the EU is a 10-year period of market exclusivity for the indication, if approved. Now read: NeuroDerm (NDRM) Investor Presentation - Slideshow » [Read more]

IMPACT SNAPSHOT EVENT TIME: PZRX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
PZRX alerts
from News Quantified
Opt-in for
PZRX alerts

from News Quantified
Opt-in for
PZRX alerts

from News Quantified